<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="117810">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02094469</url>
  </required_header>
  <id_info>
    <org_study_id>021-KOA-1302i</org_study_id>
    <nct_id>NCT02094469</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Cilostazol to Treat Vasapastic Angina</brief_title>
  <acronym>STELLA_Ext</acronym>
  <official_title>A Multicenter, One Group, Open-label Study to Evaluate the Safety and Efficacy of Pletaal(Cilostazol) as BID for up to 24 Weeks Exposure in Subjects With Vasospastic Angina (STELLA Extension)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Korea Otsuka Pharmaceutical Co.,Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Korea Otsuka Pharmaceutical Co.,Ltd.</source>
  <oversight_info>
    <authority>Korea: Ministry of Food and Drug Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted in accordance with the local regulation of New Drug
      Application. Overall duration of this trial will be 3 years after approval of MFDS.

      Each subject will participate around 26 weeks, which include the 24 weeks treatment period
      and 2 weeks safety follow up period. Withdrawn subjects due to efficacy after 4 weeks
      treatment will partcipate in 6 weeks in total including 2 weeks safety follow up. Withdrawn
      subjects with other reason also have 2 weeks follow up period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Multicenter, One group, Open-label Study. Cilostazol will be treated for additional 24
      weeks to the subject who had completed 021-KOA-1301i study. PletaalÒ(Cilostazol) is taken
      100mg oral tablets bid during 2 3weeks after dosing of PletaalÒ(Cilostazol) 50mg oral
      tablets bid during 1 week. The dose can be adjusted by investigator's discretion during the
      study and the detailed method is described in the Protocol. Subject who has 2 or more chest
      pain at 4th week will be withdrawn from the study (But, subjects who show 50% or more of
      chest pain decrease compared to 1st week would not be withdrawn.). Subjects who participated
      in this trial will have 2 weeks follow-up after study completion.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">February 2016</completion_date>
  <primary_completion_date type="Anticipated">February 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of subjects without chest pain on the final a week/final 2 weeks after 24 weeks treatment.</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Proportion of subjects without chest pain on the final a week/final 2 weeks after 24 weeks treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>secondary 1</measure>
    <time_frame>24 week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change/Percent change of the chest pain frequency on the final a week/final 2 weeks after 24 weeks treatment compared to final a week/final 2 weeks on Amlodipine run-in period of 021-KOA-1301i.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary 2</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change of the chest pain intensity on the final a week/final 2 weeks after 24 weeks treatment compared to final a week/final 2 weeks on Amlodipine run-in period of 021-KOA-1301i.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>secondary 3</measure>
    <time_frame>4 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cumulative proportion of withdrawn subjects due to lack of efficacy at every 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Vasospastic Angina</condition>
  <arm_group>
    <arm_group_label>Cilostazol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Cilostazol 50mg and 100mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cilostazol</intervention_name>
    <description>Oral, Bid, 24 weeks</description>
    <arm_group_label>Cilostazol</arm_group_label>
    <other_name>Pletaal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - 1. Male or female 20 or over the age of 20 and under the age of 80. But, patients who
        were 80 years at the time of 021-KOA-1301i enrollment and who are now 81 years, are
        eligible for this trial.

        2. Subjects who completed 021-KOA-1301i study. 3. Women must be postmenopausal (for at
        least 1 year), incapable of pregnancy, or, if sexually active and capable of pregnancy, be
        practicing an acceptable method of birth control (e.g., hormonal contraceptives,
        intrauterine device, male condom+spermicide, female condom+spermicide, male partner
        sterilization) 4. Ability to provide own written informed consent after receiving a full
        explanation for this study

        Exclusion Criteria:

          1. Subjects who have exclusion criteria at the enrollment of 021-KOA-1301i study.

          2. Subjects who have exclusion criteria from 021-KOA-1301i enrollment to visit 1 of
             021-KOA-1302i. The exclusion criteria is as below.

               -  Myocardial infarction or Myocardial infarction by vasospastic angina at
                  screening

               -  Life threatening vasospastic events such as ventricular tachycardia ,
                  ventricular fibrillation, or syncope

               -  Stroke, intracranial hemorrhage, or TIA

               -  Hemorrhage (hemophilia, capillary fragility, intracranial hemorrhage, upper
                  gastrointestinal hemorrhage, urinary hemorrhage, hemoptysis, vitreous
                  hemorrhage, etc.)

          3. Subjects who are now taking the prohibited medication of 021-KOA-1301i.
             (Investigational Products of 021-KOA-1301i are permitted.)

          4. Clinical laboratory test results of visit 1 are identified as following criteria at
             visit 2.

               -  Subjects with severe anemia of Hemoglobin ≤ 6.5 g/dl at screening

               -  Creatinine ≥ 1.5 mg/dL at screening

               -  Aspartate transaminase (AST) or alanine transaminase (ALT) &gt; 3 times the upper
                  limit of normal (ULN) at screening

               -  Platelet &lt; 100,000 mm3 at screening

          5. Tachycardia; Heart rate &gt; 100 bpm, at Screening via vital sign

          6. Hypotension of diastolic pressure &lt; 90 mmHg at screening

          7. Uncontrolled hypertension, defined as ≥ 160 mmHg systolic or ≥ 100 mmHg diastolic at
             Screening

          8. QT prolongation defined as baseline QTcB &gt; 450 msec for males or QTcB &gt; 470 msec for
             females at Screening.

          9. Women of childbearing potential who have positive pregnancy test result at screening
             -
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junghong Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yangsan Busan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yangsan Busan University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>626-770</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junghong Kim, MD</last_name>
      <phone>82-10-8231-7171</phone>
      <email>junehongk@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>March 20, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Treatment for vasospastic angina</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina Pectoris, Variant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cilostazol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
